8-K: Hepion Pharmaceuticals In-Licenses Diagnostic Tests, Expands Portfolio

Hepion Pharmaceuticals enters a binding agreement to in-license diagnostic tests for various diseases, including celiac disease and hepatocellular carcinoma, from New Day Diagnostics LLC.

Summary

• Hepion Pharmaceuticals has entered into a binding letter of intent with New Day Diagnostics LLC to in-license certain diagnostic tests.
• The tests include diagnostics for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC).
• The celiac, respiratory multiplex, and H. pylori tests already have CE marks and can be sold in Europe.
• Hepion will pay $525,000 in cash and $200,000 in common stock to New Day.
• Additionally, Hepion will pay up to $17.15 million upon achieving certain regulatory, sales, and reimbursement milestones.
• New Day will also receive royalty rates in the upper single to low double digits based on net sales.
• The parties intend to enter into a definitive license agreement, but the Binding LOI is binding and can only be terminated with mutual consent.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is expanding its portfolio through in-licensing, which could lead to future revenue streams. However, the success depends on achieving milestones and market acceptance.

Positives

• Hepion gains access to diagnostic tests with existing CE marks for sale in Europe.
• The in-licensing agreement diversifies Hepion's portfolio into diagnostics.
• The milestone-based payment structure aligns incentives with successful development and commercialization.

Risks

• The definitive license agreement is yet to be finalized, although the Binding LOI is binding.
• The success of the diagnostic tests depends on achieving regulatory approvals, sales targets, and reimbursement milestones.
• The royalty rates could impact profitability depending on the net sales achieved.

Future Outlook

The parties contemplate entering into a definitive license agreement.

Management Comments

• John Brancaccio, Interim Chief Executive Officer and Interim Chief Financial Officer, signed the report on behalf of Hepion Pharmaceuticals.

Industry Context

The in-licensing of diagnostic tests reflects a trend in the pharmaceutical industry to diversify product portfolios and leverage external innovation. Diagnostic tests are becoming increasingly important for personalized medicine and targeted therapies.

Comparison to Industry Standards

• In-licensing diagnostic tests is a common strategy among pharmaceutical companies to expand their product offerings.
• Companies like Roche and Abbott have extensive diagnostic portfolios acquired through similar deals.
• The financial terms of the agreement, including upfront payments, milestone payments, and royalty rates, are within the typical range for such transactions in the diagnostics industry.

Stakeholder Impact

• Shareholders may view the in-licensing agreement positively as it diversifies the company's portfolio.
• Employees may see new opportunities in the diagnostics area.
• Customers (healthcare providers) could benefit from access to new diagnostic tools.
• New Day Diagnostics benefits from the upfront payments, potential milestone payments, and royalties.

Next Steps

• Finalizing the definitive license agreement with New Day Diagnostics.
• Pursuing regulatory approvals for the diagnostic tests.
• Achieving sales and reimbursement milestones to trigger additional payments.
• Commercializing the diagnostic tests, particularly in Europe for those with CE marks.

Key Dates

Keywords

Hepion Pharmaceuticals, New Day Diagnostics, in-licensing, diagnostic tests, celiac disease, respiratory multiplex, H. pylori, hepatocellular carcinoma, CE mark, milestones, royalties